Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125273231 | 12527323 | 1 | I | 20160530 | 20160614 | 20160705 | 20160705 | EXP | JP-ELI_LILLY_AND_COMPANY-JP201606005085 | ELI LILLY AND CO | 49.00 | YR | F | Y | 0.00000 | 20160704 | CN | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125273231 | 12527323 | 1 | PS | ZYPREXA | OLANZAPINE | 1 | Oral | 2.5 MG, QD | 20592 | 2.5 | MG | QD | |||||||
| 125273231 | 12527323 | 2 | SS | TAMOXIFEN | TAMOXIFEN | 1 | U | 0 | |||||||||||
| 125273231 | 12527323 | 3 | C | LIPIDIL | FENOFIBRATE | 1 | 0 | ||||||||||||
| 125273231 | 12527323 | 4 | C | URSO | URSODIOL | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125273231 | 12527323 | 1 | Depression |
| 125273231 | 12527323 | 2 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125273231 | 12527323 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125273231 | 12527323 | Off label use | |
| 125273231 | 12527323 | Pulmonary hypertension |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125273231 | 12527323 | 1 | 2011 | 0 |